what is difference in semaglutide and tirzepatide key differences, weight loss results (2026) Tirzepatide vs. Ozempic: Comparing Diabetes

A Renewed Look at an Old Controversy The 2025 J Clin Med: The Cleanest Lens Yet The 2025 Am J Gastroenterology: Better Outcomes, Not Worse The 2025 Diabetes Metabolism: Even Safe After Prior Pancreatitis Historical Context: The Arc of Evidence Why the Myth Persisted Clinical Implications: How to Translate This in Practice Illustrative Cases Summary Table A Balanced Perspective Read More To view or add a comment, sign in Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events

As the ABC noted in its reporting on the Victorian cases, the injectable medication has not been approved by any worldwide drug regulator. It is still moving through clinical trials, where it is one of the most effective compounds the obesity field has ever produced

KC: Data curation, Project administration, Writing original draft, Writing review & editing

Lastly, the $700 billion in market capitalization gains by Novo Nordisk and Eli Lilly since the launch of GLP-1 therapies is a stark indicator of financialization, as these valuations far exceed the cumulative revenue generated by the drugs themselves